Hygeia Therapeutics Inc., a Holden life sciences company that makes skin treatments, has received $1 million in financing to help develop two of its products.
The company plans to continue testing HYG-102, a topical synthetic estrogen for treating atrophy, as well as accelerate development of HYG-440, an acne medication.
The company is hoping to develop localized treatments for conditions that can be used instead of systemic therapies.
The company was founded in 2007 and received the Series A funding from Walter Greenblatt & Associates, a New Jersey biotechnology venture firm.
